1. Show article details.

    U.S. administers 386.8 mln doses of COVID-19 vaccines - CDC

    Reuters – 5:32 PM ET 09/21/2021

    The United States has administered 386,780,816 doses of COVID-19 vaccines in the country as of Tuesday morning and distributed 467,249,715 doses, the U.S. Centers for Disease Control and Prevention said. Those figures are up from the 386,237,881 vaccine doses the CDC said had gone into arms by Sept. 20.

  2. Show article details.

    BRIEF-U.S. CDC Says Delivered 467,249,715 Doses Of Covid-19 Vaccine As Of Sept 21

    Reuters – 5:28 PM ET 09/21/2021

    U.S. CDC : * U.S. CDC SAYS DELIVERED 467,249,715 DOSES OF COVID-19 VACCINE AS OF SEPT 21 VERSUS 466,535,855 DOSES DELIVERED AS OF SEPT 20. * U.S. CDC SAYS ADMINISTERED 386,780,816 DOSES OF COVID-19 VACCINE AS OF SEPT 21 VERSUS 386,237,881 DOSES ADMINISTERED AS OF SEPT 20. * U.S. CDC SAYS 2.24 MILLION PEOPLE RECEIVED AN ADDITIONAL COVID-19 VACCINE DOSE SINCE AUGUST 13, 2021.

  3. Show article details.

    India govt won't buy Pfizer, Moderna vaccines amid local output -sources

    Reuters – 9:09 AM ET 09/21/2021

    India's government will not buy COVID-19 shots from Pfizer/BioNTech and Moderna (MRNA), three government sources told Reuters, mainly because domestic output of more affordable and easier-to-store vaccines has jumped https://www.reuters.com/world/india/how-india-flipped-its-vaccine-fortunes-2021-09-21.

  4. Show article details.

    EU says people vaccinated with AstraZeneca shots should be able to travel to U.S.

    Reuters – 7:10 AM ET 09/21/2021

    The European Commission said on Tuesday it would make sense for the United States to allow travel by people vaccinated with the AstraZeneca COVID-19 shots, although existing U.S. guidance already authorises those travellers. On Monday, the White House said it would lift restrictions from November that bar EU citizens, including those fully vaccinated, from traveling to the United States.

  5. Show article details.

    BRIEF-J&J Announces Real-World-Evidence And Phase 3 Data Confirming Strong And Long-Lasting Protection Of Single-Shot Covid-19 Vaccine In The U.S

    Reuters – 6:57 AM ET 09/21/2021

    J&J: * J&J ANNOUNCES REAL-WORLD-EVIDENCE AND PHASE 3 DATA CONFIRMING STRONG AND LONG-LASTING PROTECTION OF SINGLE-SHOT COVID-19 VACCINE IN THE U.S. * J&J - SAFETY PROFILE OF COVID-19 VACCINE REMAINED CONSISTENT, WAS GENERALLY WELL TOLERATED WHEN ADMINISTERED AS A BOOSTER. * J&J - AGAINST SYMPTOMATIC COVID-19, BOOSTER SHOT AT 2 MONTHS PROVIDED 94% PROTECTION IN U.S., 75% PROTECTION GLOBALLY.

  6. Show article details.

    J&J says second shot boosts protection for moderate-severe COVID-19 to 94%

    Reuters – 6:30 AM ET 09/21/2021

    Johnson & Johnson (JNJ) said Tuesday a second shot of its COVID-19 vaccine given about two months after the first increased its effectiveness to 94% in the United States against moderate to severe forms of the disease. That compares to 70% protection with a single dose.

  7. Show article details.

    Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.

    PR Newswire – 6:30 AM ET 09/21/2021

    NEW BRUNSWICK, N.J., Sept. 21, 2021  Johnson & Johnson (JNJ) today announced new data reinforcing the strong and long-lasting protection of its COVID-19 vaccine. "Our large real-world evidence and Phase 3 studies confirm that the single-shot Johnson & Johnson (JNJ) vaccine provides strong and long-lasting protection against COVID-19-related hospitalizations.

  8. Show article details.

    U.S. administers 386.2 mln doses of COVID-19 vaccines - CDC

    Reuters – 2:34 PM ET 09/20/2021

    The United States has administered 386,237,881 doses of COVID-19 vaccines in the country as of Monday morning, the U.S. Centers for Disease Control and Prevention said. Those figures are up from the 385,586,012 vaccine doses the CDC said had gone into arms by Sept. 19.

  9. Show article details.

    BRIEF-U.S. CDC Says Administered About 386.2 Million Doses Of Covid-19 Vaccine As Of Sept 20

    Reuters – 2:22 PM ET 09/20/2021

    U.S. CDC: * U.S. CDC SAYS DELIVERED 466,535,855 DOSES OF COVID-19 VACCINE AS OF SEPT 20. * U.S. CDC SAYS ADMINISTERED 386,237,881 DOSES OF COVID-19 VACCINE AS OF SEPT 20 VERSUS 385,586,012 DOSES ADMINISTERED AS OF SEPT 19. * U.S. CDC SAYS 212,035,328 INDIVIDUALS HAVE RECEIVED AT LEAST ONE DOSE OF COVID-19 VACCINE AS OF SEPT 20 VERSUS 211,776,515 INDIVIDUALS AS OF SEPT 19.

  10. Show article details.

    Regulators could OK Pfizer boosters for older Americans this week

    Reuters – 12:30 PM ET 09/20/2021

    U.S. regulators could authorize a booster shot of the Pfizer Inc/BioNTech SE COVID-19 vaccine for older and some high-risk Americans early this week in time for the government to roll them out by Friday.

  11. Show article details.

    India set to get first J&J COVID vaccine doses in October, says source

    Reuters – 12:09 PM ET 09/20/2021

    India expects to get its first Johnson & Johnson COVID-19 vaccine doses from next month, filled and finished in India by a partner of the U.S. drugmaker, a source with knowledge of the matter told Reuters on Monday.

  12. Show article details.

    Regulators expected to OK Pfizer boosters for older Americans this week

    Reuters – 6:00 AM ET 09/20/2021

    U.S. regulators are expected to authorize a third booster shot of the Pfizer Inc (PFE) /BioNTech SE COVID-19 vaccine for older and some high-risk Americans early this week in time for the government to roll them out by Friday as hoped.

  13. Show article details.

    BRIEF-Mauna Kea Technologies: New Clinical Study, Research Collaboration Agreement With Lung Cancer Initiative At Johnson & Johnson

    Reuters – 1:52 AM ET 09/20/2021

    Mauna Kea Technologies SAS: * MAUNA KEA TECHNOLOGIES ANNOUNCES NEW CLINICAL STUDY AND RESEARCH COLLABORATION AGREEMENT WITH THE LUNG CANCER INITIATIVE AT JOHNSON & JOHNSON (JNJ). * MAUNA KEA TECHNOLOGIES WILL PARTICIPATE IN A PROSPECTIVE, MULTI-CENTER, OPEN-LABEL, SINGLE-ARM CLINICAL FEASIBILITY STUDY LED BY LCI.

  14. Show article details.

    U.S. administers about 385.6 mln doses of COVID-19 vaccines -CDC

    Reuters – 2:29 PM ET 09/19/2021

    The United States has administered 385,586,012 doses of COVID-19 vaccines as of Sunday morning and distributed 466,561,785 doses, the U.S. Centers for Disease Control and Prevention said. Those figures are up from 384,911,290 vaccine doses the CDC said had gone into arms by Sept. 18 out of 466,569,635 doses delivered.

  15. Show article details.

    BRIEF-U.S. CDC Says Administered 385,586,012 Doses Of COVID-19 Vaccine As Of Sept 19

    Reuters – 2:17 PM ET 09/19/2021

    BioNTech SE: * U.S. CDC SAYS DELIVERED 466,561,785 DOSES OF COVID-19 VACCINE AS OF SEPT 19 VERSUS 466,569,635 DOSES DELIVERED AS OF SEPT 18. * U.S. CDC SAYS 211,776,515 INDIVIDUALS HAVE RECEIVED AT LEAST ONE DOSE OF COVID-19 VACCINE AS OF SEPT 19 VERSUS 211,489,242 INDIVIDUALS AS OF SEPT 18.

  16. Show article details.

    Key data on U.S. J&J, Moderna COVID-19 boosters 'weeks away,' Fauci says

    Reuters – 12:29 PM ET 09/19/2021

    Data needed to determine the advisability of booster shots of the Moderna Inc (MRNA) and Johnson & Johnson COVID-19 vaccines is just weeks away, President Joe Biden's chief medical adviser said on Sunday, as officials signaled they expected boosters would be recommended for a broad swath of Americans. U.S. health regulators already have begun to consider a third dose of the Pfizer/BioNTech vaccine.

  17. Show article details.

    BRIEF-Janssen Says Rybrevant Provides Higher Activity, Longer Duration Of Response When Used In Combination With Lazertinib

    Reuters – 11:45 AM ET 09/19/2021

    Johnson & Johnson (JNJ): * JANSSEN PHARMACEUTICALS - ANNOUNCED A NEW ANALYSIS FROM STUDY EVALUATING RYBREVANT. * JANSSEN - RYBREVANT PROVIDES HIGHER ACTIVITY, LONGER DURATION OF RESPONSE WHEN USED IN COMBINATION WITH LAZERTINIB IN PATIENTS WITH LUNG CANCER Source text for Eikon: Further company coverage:

  18. Show article details.

    World leaders return to U.N. with focus on pandemic, climate

    Reuters – 12:01 AM ET 09/19/2021

    World leaders are returning to the United Nations in New York this week with a focus on boosting efforts to fight both climate change and the COVID-19 pandemic, which last year forced them to send video statements for the annual gathering.

  19. Show article details.

    U.S. administers about 384.9 mln doses of COVID-19 vaccines -CDC

    Reuters – 5:25 PM ET 09/18/2021

    The United States has administered 384,911,290 doses of COVID-19 vaccines as of Saturday morning and distributed 466,569,635 doses, the U.S. Centers for Disease Control and Prevention said. Those figures are up from 383,994,877 vaccine doses the CDC said had gone into arms by Sept. 17 out of 464,315,725 doses delivered.

  20. Show article details.

    BRIEF-U.S. CDC Says Administered 384,911,290 Doses Of COVID-19 Vaccine As Of Sept 18

    Reuters – 5:22 PM ET 09/18/2021

    * U.S. CDC SAYS ADMINISTERED 384,911,290 DOSES OF COVID-19 VACCINE AS OF SEPT 18 VERSUS 383,994,877 DOSES ADMINISTERED AS OF SEPT 17. * U.S. CDC SAYS DELIVERED 466,569,635 DOSES OF COVID-19 VACCINE AS OF SEPT 18 VERSUS 464,315,725 DOSES DELIVERED AS OF SEPT 17.

Page:

Today's and Upcoming Events

  • Oct
    19

    JNJ to announce Q3 earnings (Confirmed)

Past Events (last 90 days)

  • Aug
    23

    JNJ ex-Dividend for $1.06 on 08/23/2021

    • Announce Date: 07/19/2021
    • Record Date: 08/24/2021
    • Pay Date: 09/07/2021
  • Jul
    21

    JNJ announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.